Everolimus for Previously Treated Advanced Gastric Cancer: Results of the Randomized, Double-Blind, Phase III GRANITE-1 Study | Zendy

Atsushi Ohtsu | Zendy; Jaffer A. Ajani | Zendy; Yu-Xian Bai | Zendy; YungJue Bang | Zendy; Hyun Cheol Chung | Zendy; Hong-Ming Pan | Zendy; Tarek Sahmoud | Zendy; Lin Shen | Zendy; KunHuei Yeh | Zendy; Keisho Chìn | Zendy; Kei Muro | Zendy; Yeul Hong Kim | Zendy; David Ferry | Zendy; Niall C. Tebbutt | Zendy; SalahEddin AlBatran | Zendy; Heind Smith | Zendy; Chiara Costantini | Zendy; Syed Rizvi | Zendy; David Lebwohl | Zendy; Eric Van Cutsem | Zendy

Open Access

Everolimus for Previously Treated Advanced Gastric Cancer: Results of the Randomized, Double-Blind, Phase III GRANITE-1 Study

Author(s) -

Atsushi Ohtsu,

Jaffer A. Ajani,

Yu-Xian Bai,

YungJue Bang,

Hyun Cheol Chung,

Hong-Ming Pan,

Tarek Sahmoud,

Lin Shen,

KunHuei Yeh,

Keisho Chìn,

Kei Muro,

Yeul Hong Kim,

David Ferry,

Niall C. Tebbutt,

SalahEddin AlBatran,

Heind Smith,

Chiara Costantini,

Syed Rizvi,

David Lebwohl,

Eric Van Cutsem

Publication year - 2013

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.2012.48.3552

Subject(s) - everolimus , medicine , ramucirumab , hazard ratio , clinical endpoint , adverse effect , cancer , placebo , phases of clinical research , gastroenterology , chemotherapy , surgery , oncology , clinical trial , confidence interval , pathology , alternative medicine

The oral mammalian target of rapamycin inhibitor everolimus demonstrated promising efficacy in a phase II study of pretreated advanced gastric cancer. This international, double-blind, phase III study compared everolimus efficacy and safety with that of best supportive care (BSC) in previously treated advanced gastric cancer.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research